- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13:00 | Radiopharm Theranostics Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 12:18 | Radiopharm doses first patient in RAD 402 prostate cancer trial | 1 | Investing.com | ||
| 12:06 | Radiopharm Theranostics Doses First Patient in Phase 1 Clinical Study of RAD 402 in Advanced Prostate Cancer | 75 | GlobeNewswire (Europe) | On track to share data from first two dose levels in 2H 2026 Targeting KLK3 and leveraging the dual emission of Tb161 represents an innovative approach for radiotherapies in Prostate Cancer Preclinical... ► Artikel lesen | |
| 03:10 | Radiopharm Theranostics doses first patient in prostate cancer clinical study | 1 | The Market Herald Australia | ||
| Do | RADIOPHARM THERANOSTICS LIMITED: RAD Doses First Patient in RAD 402 Phase 1 Clinical Study | - | ASX | ||
| RADIOPHARM THERANOSTICS Aktie jetzt für 0€ handeln | |||||
| Di | Radiopharm Theranostics Eyes Pivotal Trial Path After Encouraging Interim Results | 1 | Benzinga.com | ||
| Mo | RADIOPHARM THERANOSTICS LIMITED: RAD101 2nd interim Ph.2b data - 90% achieve primary endpoint | - | ASX | ||
| 19.03. | Radiopharm Theranostics Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 19.03. | RADIOPHARM THERANOSTICS LIMITED: RAD to present at NWR Virtual Healthcare Conference | 3 | ASX | ||
| 27.02. | RADIOPHARM THERANOSTICS LIMITED: Half Year Report and Appendix 4D 31 December 2025 | 3 | ASX | ||
| 24.02. | AtomVie Global Radiopharma Inc.: AtomVie Global Radiopharma Supplies First Patient Dose in Radiopharm Theranostics' Phase 1/2a Clinical Study of 177Lu-BetaBart (RV-01) | 357 | PR Newswire | HAMILTON, ON, Feb. 24, 2026 /PRNewswire/ -- AtomVie Global Radiopharma (AtomVie), a global leading radiopharmaceutical CDMO, announced that it has supplied the successful dosing of the first... ► Artikel lesen | |
| 24.02. | Radiopharm Theranostics Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 24.02. | Radiopharm doses first patient in phase 1/2a cancer trial | 1 | Investing.com | ||
| 24.02. | Radiopharm Theranostics Doses First Patient in Phase 1/2a Clinical Study of BetaBart (RV-01) | 260 | GlobeNewswire (Europe) | First radiotherapeutic agent developed by Radiopharm Ventures, the joint venture between Radiopharm Theranostics and MD Anderson Cancer Center Preclinical animal studies of BetaBart (RV-01) have... ► Artikel lesen | |
| 24.02. | Radiopharm Theranostics Doses First Patient in RV-01 Phase 1/2a Trial for Aggressive Cancers | 2 | smallcaps.com.au | ||
| 23.02. | RADIOPHARM THERANOSTICS LIMITED: RAD Doses First Patient in 177Lu-BetaBart (RV-01) Study | - | ASX | ||
| 28.01. | Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates | 311 | GlobeNewswire (Europe) | Interim results from Phase 2b clinical trial of RAD 101 showed 92% of evaluable participants met the primary endpoint of MRI concordance in imaging study of patients with brain metastases Interim... ► Artikel lesen | |
| 28.01. | Radiopharm Theranostics Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 27.01. | RADIOPHARM THERANOSTICS LIMITED: Quarterly Activities/Appendix 4C Cash Flow Report | - | ASX | ||
| 12.01. | Radiopharm Theranostics: RAD Increases Ownership in Radiopharm Ventures to 87.5% | 252 | GlobeNewswire (Europe) | Radiopharm Ventures, LLC, is a joint venture created in 2022 between MD Anderson Cancer Center and Radiopharm TheranosticsLeading candidate Betabart, a monoclonal antibody targeting B7H3, has received... ► Artikel lesen |
1 2 3 4 5 Weiter >>
103 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 33,900 | -3,32 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| ARTELO BIOSCIENCES | 10,140 | +217,87 % | Morning Market Movers: Artelo Biosciences, Onconetix, Datacentrex, Robin Energy See Big Swings | OTTAWA (dpa-AFX) - At 8:30 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| ONCONETIX | 4,300 | +35,22 % | XFRA ISIN CHANGE | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenUS68237Q2030 Onconetix Inc. 24.03.2026 US68237Q3020 Onconetix Inc. 25.03.2026 Tausch 5:1US98386D3070 XTL Biopharmaceuticals... ► Artikel lesen | |
| ADMA BIOLOGICS | 9,520 | +14,98 % | ADMA Biologics, Inc.: ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research | Short seller's Characterization of ASCENIV's Competitive Position Reflects Blatant Misunderstanding of ADMA's Business and Its Role as Late-line Therapy for Patients Who are Immune Compromised and... ► Artikel lesen | |
| EVOTEC | 4,304 | -1,62 % | Aktien KW 12 Iran Krieg und kein Ende? TACO fällt aus? Weltweite Rezession? News. Evotec. Ottobock. SFC Energy. All for One. Exasol. Softing. freenet. Mensch und Maschine. ThyssenKrupp nucera. HomeToGo. Aumann. Doc Morris. Fuchs. Krones. MAX Automation. U | Aktien: Wie letzte Woche - eine weitere Woche Bomben auf den Iran, keine erkennbaren "Erfolge" - ausser das sinnlos Menschen sterben. Und rekordhohe Ölpreise, Erdgas teurer als in der Ukraine-Preishochphase.... ► Artikel lesen | |
| BIONTECH | 75,90 | 0,00 % | Biotech-Werte im Check: Warum Emyria, Newron und BioNTech jetzt auf Substanz statt Hoffnung setzen | ||
| VERA THERAPEUTICS | 40,270 | 0,00 % | Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer | BRISBANE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients... ► Artikel lesen | |
| ARCELLX | 114,61 | +0,07 % | Arcellx legt Zahlen vor - Augenmerk liegt auf Gilead-Übernahme | ||
| ZENAS BIOPHARMA | 17,500 | -21,10 % | Zenas BioPharma Prices $300M Capital Raise in Dual Offering | ||
| C4 THERAPEUTICS | 2,505 | -4,75 % | C4 Therapeutics, Inc.: C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO) for Relapsed/Refractory Multiple Myeloma | WATERTOWN, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 38,910 | -0,69 % | Enliven Therapeutics stock price target raised to $56 by H.C. Wainwright | ||
| ALUMIS | 25,020 | -4,94 % | Alumis Inc.: Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements | - Positive Phase 3 topline results demonstrating envudeucitinib's leading skin clearance, meaningful symptom improvement and a favorable safety profile in patients with moderate-to-severe plaque psoriasis... ► Artikel lesen | |
| REGENCELL BIOSCIENCE | 25,390 | 0,00 % | Here's Why I Wouldn't Touch Regencell Bioscience With a 10-Foot Pole Right Now | ||
| DAY ONE BIOPHARMACEUTICALS | 21,425 | +0,05 % | Weekly Buzz: Bristol Myers Squibb Wins FDA Nod; EU Okays Johnson & Johnson's AKEEGA; Ipsen Withdraws Tazverik, Day One Biopharmaceuticals Acquired | NEW BRUNSWICK (dpa-AFX) - This week's biotech landscape witnessed key FDA approvals, EU approvals, IND clearances, acquisitions, and clinical trial data readouts across key therapeutic areas... ► Artikel lesen | |
| BB BIOTECH | 46,650 | -1,27 % | Dividendenbekanntmachungen (23.03.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABB LTD CH0012221716 0,94 CHF 1,0309 EUR AECON GROUP INC CA00762V1094 0,1925 CAD 0,1212 EUR AMPHENOL CORPORATION US0320951017 0... ► Artikel lesen |
Das Unternehmen RADIOPHARM THERANOSTICS LIMITED ADR kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 4,200 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RADIOPHARM THERANOSTICS LIMITED ADR finden Sie auf Wallstreet Online.